The Pulse of the MedTech Industry Report 2024 from EY is now available for download! While research shows that the MedTech industry is still growing, it is increasingly walking a narrow path between converging top-line and bottom-line pressures. With deep insights from EY thought leaders and perspectives from top MedTech executives on the current financing environment, capital efficiency viewpoints, what’s next in MedTech financing, and the future of innovation, the EY analysis on the state of the industry leaves no stone unturned.
Click here for details: www.ey.com/pulse
Related Reading
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders
On Demand
Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance metrics, payment pathways, and opportunities for the MedTech industry.
News / Global & Trade / Tariffs
ICYMI: AdvaMed’s Scott Whitaker on Supreme Court Tariffs Decision, Next Steps
February 23, 2026
Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
Now On Demand
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
News / Global & Trade / Supply Chain / Tariffs
AdvaMed® Supports United States-Mexico-Canada Agreement Renewal
February 12, 2026
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed® president and CEO, made the following comment on the renewal.
Resource / AdvaMed Advancements / Global & Trade / Tariffs
AdvaMed® Plays Tariff Chess, Trump Plays Checkers
February 4, 2026
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q4 2025 Report
January 27, 2026
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
News / China / Global & Trade / Supply Chain / Tariffs
AdvaMed® Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
November 3, 2025
WASHINGTON—AdvaMed, the MedTech Association®, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q3 2025 Report
October 31, 2025
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment,AdvaMed® remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more